BGLC
vs
S&P 500
BGLC
S&P 500
Over the past 12 months, BGLC has underperformed S&P 500, delivering a return of +4% compared to the S&P 500's +30% growth.
Stocks Performance
BGLC vs S&P 500
Performance Gap
BGLC vs S&P 500
Performance By Year
BGLC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
BioNexus Gene Lab Corp
Glance View
BioNexus Gene Lab Corp. is a molecular diagnostics company, which focuses on the application of functional genomics to enable diagnosis and personalized health management. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan and currently employs 8 full-time employees. The company went IPO on 2020-03-11. The firm is focused on the application of functional genomics to enable early diagnosis and personalized health management. The firm's wholly owned subsidiaries include Bionexus Gene Lab Sdn. Bhd. (Bionexus Malaysia) and Chemrex Sdn. Bhd. (Chemrex). BioNexus Malaysia owns algorithm software, technology and know-how related to the detection of common diseases through blood analysis which it uses in its business. Its non-invasive blood screening tests analyze changes in ribonucleic acid (RNA) to detect the risk potentiality of approximately 11 different diseases. These diseases include cancers, bowel diseases and osteoarthritis. Chemrex is a wholesaler of industrial chemicals for the manufacture of industrial, medical, appliance, aero, automotive, mechanical and electronic industries in Asia Pacific region.
